BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wathen MW, Barro M, Bright RA. Antivirals in seasonal and pandemic influenza--future perspectives. Influenza Other Respir Viruses 2013;7 Suppl 1:76-80. [PMID: 23279900 DOI: 10.1111/irv.12049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Yan H, Ma L, Wang H, Wu S, Huang H, Gu Z, Jiang J, Li Y. Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. J Nat Med 2019;73:487-96. [PMID: 30758716 DOI: 10.1007/s11418-019-01287-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
2 Vegvari C, Hadjichrysanthou C, Cauët E, Lawrence E, Cori A, de Wolf F, Anderson RM. How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections? PLoS One 2016;11:e0158237. [PMID: 27367230 DOI: 10.1371/journal.pone.0158237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
3 Herold S, Becker C, Ridge KM, Budinger GR. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J 2015;45:1463-78. [PMID: 25792631 DOI: 10.1183/09031936.00186214] [Cited by in Crossref: 174] [Cited by in F6Publishing: 170] [Article Influence: 24.9] [Reference Citation Analysis]
4 Mosier PD, Chiang MJ, Lin Z, Gao Y, Althufairi B, Zhou Q, Musayev F, Safo MK, Xie H, Desai UR. Broad Spectrum Anti-Influenza Agents by Inhibiting Self-Association of Matrix Protein 1. Sci Rep 2016;6:32340. [PMID: 27573445 DOI: 10.1038/srep32340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
5 Singer AC, Järhult JD, Grabic R, Khan GA, Lindberg RH, Fedorova G, Fick J, Bowes MJ, Olsen B, Söderström H. Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers. PLoS One 2014;9:e108621. [PMID: 25254643 DOI: 10.1371/journal.pone.0108621] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
6 Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. The sweet spot: defining virus-sialic acid interactions. Nat Rev Microbiol 2014;12:739-49. [PMID: 25263223 DOI: 10.1038/nrmicro3346] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 22.4] [Reference Citation Analysis]
7 Graham AC, Temple RM, Obar JJ. Mast cells and influenza a virus: association with allergic responses and beyond. Front Immunol 2015;6:238. [PMID: 26042121 DOI: 10.3389/fimmu.2015.00238] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
8 Dunning J, Baillie JK, Cao B, Hayden FG; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis 2014;14:1259-70. [PMID: 25213733 DOI: 10.1016/S1473-3099(14)70821-7] [Cited by in Crossref: 100] [Cited by in F6Publishing: 59] [Article Influence: 12.5] [Reference Citation Analysis]
9 Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother 2014;58:2718-30. [PMID: 24566185 DOI: 10.1128/AAC.02628-13] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
10 Heldt FS, Frensing T, Pflugmacher A, Gröpler R, Peschel B, Reichl U. Multiscale modeling of influenza A virus infection supports the development of direct-acting antivirals. PLoS Comput Biol 2013;9:e1003372. [PMID: 24278009 DOI: 10.1371/journal.pcbi.1003372] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
11 Nguyen HT, Nguyen T, Mishin VP, Sleeman K, Balish A, Jones J, Creanga A, Marjuki H, Uyeki TM, Nguyen DH, Nguyen DT, Do HT, Klimov AI, Davis CT, Gubareva LV. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011. Emerg Infect Dis 2013;19:1963-71. [PMID: 24274711 DOI: 10.3201/eid1912.130705] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
12 Hayden FG. Advances in antivirals for non-influenza respiratory virus infections. Influenza Other Respir Viruses 2013;7 Suppl 3:36-43. [PMID: 24215380 DOI: 10.1111/irv.12173] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
13 Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA, Sanicas M. The emerging influenza virus threat: status and new prospects for its therapy and control. Arch Virol 2018;163:831-44. [PMID: 29322273 DOI: 10.1007/s00705-018-3708-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
14 van der Vries E, Schutten M, Fraaij P, Boucher C, Osterhaus A. Influenza virus resistance to antiviral therapy. Adv Pharmacol 2013;67:217-46. [PMID: 23886002 DOI: 10.1016/B978-0-12-405880-4.00006-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
15 Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers 2015;104:291-309. [PMID: 25663018 DOI: 10.1002/bip.22623] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
16 Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV. Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013. Antimicrob Agents Chemother 2014;58:2045-51. [PMID: 24449767 DOI: 10.1128/AAC.02556-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
17 Orr-Burks N, Murray J, Todd KV, Bakre A, Tripp RA. G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication. J Virol 2021;95:e02410-20. [PMID: 33536179 DOI: 10.1128/JVI.02410-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci 2014;1323:115-39. [PMID: 24891213 DOI: 10.1111/nyas.12462] [Cited by in Crossref: 182] [Cited by in F6Publishing: 152] [Article Influence: 22.8] [Reference Citation Analysis]
19 Orr-Burks N, Murray J, Todd KV, Bakre A, Tripp RA. Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro. PLoS One 2021;16:e0259129. [PMID: 34714852 DOI: 10.1371/journal.pone.0259129] [Reference Citation Analysis]
20 Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 2015;59:1569-82. [PMID: 25547360 DOI: 10.1128/AAC.04623-14] [Cited by in Crossref: 115] [Cited by in F6Publishing: 56] [Article Influence: 14.4] [Reference Citation Analysis]